Market Overview - The medical device sector experienced a decline of 1.98% on February 2, with Hai Li Biological leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Top Performers - Mai Pu Medical (301033) saw a closing price of 73.70, with an increase of 8.35% and a trading volume of 31,100 shares, totaling 223 million yuan [1] - Nanwei Co., Ltd. (603880) closed at 6.63, up 5.41%, with a trading volume of 191,200 shares, amounting to 126 million yuan [1] - Gongdong Medical (605369) closed at 19.46, up 2.91%, with a trading volume of 44,800 shares, totaling 86.97 million yuan [1] Underperformers - Hai Li Biological (603718) closed at 5.84, down 10.02%, with a trading volume of 84,500 shares, totaling 49.32 million yuan [2] - Yuanmei Medical (002950) closed at 10.46, down 9.52%, with a trading volume of 255,000 shares, amounting to 269 million yuan [2] - Yikang Technology (688301) closed at 111.34, down 5.92%, with a trading volume of 44,200 shares, totaling 503 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 533 million yuan from institutional investors, while retail investors experienced a net inflow of 174 million yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors showed interest [2] Individual Stock Capital Flow - Sino Medical (688108) had a net inflow of 46.28 million yuan from institutional investors, while retail investors saw a net outflow of 58.30 million yuan [3] - Mai Pu Medical (301033) experienced a net inflow of 29.68 million yuan from institutional investors, with a net outflow of 34.84 million yuan from retail investors [3] - Gongdong Medical (605369) had a net inflow of 13.18 million yuan from institutional investors, while retail investors faced a net outflow of 9.00 million yuan [3]

Core Viewpoint - Haili Biological experienced a significant stock decline, hitting the daily limit down of 10.02% to 5.84 CNY per share following the release of its 2025 performance forecast, which indicates potential delisting risk due to expected financial underperformance [1] Financial Performance Summary - The company forecasts a net profit attributable to shareholders for 2025 between 11 million to 16 million CNY, with a non-recurring net profit expected to be between -390 million to -400 million CNY [1] - Expected operating revenue for 2025 is projected to be between 190 million to 195 million CNY, which is below the 300 million CNY threshold [1] Stock Market Response - Following the announcement, Haili Biological's stock price fell to the limit down, reflecting investor concerns regarding the company's financial outlook and potential delisting risk as per the Shanghai Stock Exchange regulations [1] Management Actions - In response to the situation, the company's general manager, Han Benyi, announced plans to voluntarily increase his stake in the company, committing to invest between 1.5 million to 2 million CNY over the next six months to bolster investor confidence [1]

Group 1 - The company expects to achieve a total profit of 34 million to 40 million yuan in 2025, with a net profit attributable to the parent company of 11 million to 16 million yuan, and a net profit after deducting non-recurring gains and losses of -400 million to -390 million yuan [1] - The anticipated operating revenue for 2025 is projected to be between 190 million to 195 million yuan, which is below 300 million yuan [1] - The decline in performance is primarily due to the high comparison base from the previous year, where the company realized over 100 million yuan in investment income from the sale of a 30% non-controlling stake in WuXi Vaccines [1] Group 2 - The company's subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., is expected to experience significant performance decline starting from the second quarter of 2025 due to increased competition leading to a "price war" and tightening of previously applicable tax incentives [2] - As a result of the performance decline, the valuation based on the original acquisition's shareholder equity value is no longer reflective, leading to a supplemental agreement with the counterparty, Meilun Management Co., Ltd., to adjust the transaction price from 935 million yuan to 536 million yuan, with a return of the price difference of 399 million yuan [2]

Core Viewpoint - Haili Biological (603718.SH) announced a voluntary share buyback plan by its General Manager Han Benyi, aimed at enhancing shareholder value and investor confidence [1] Summary by Categories Company Actions - The company plans to increase its shareholding through the Shanghai Stock Exchange trading system within six months from the announcement date [1] - The total amount of the planned share buyback is expected to be no less than RMB 1.5 million and no more than RMB 2 million [1] - There is no specified price range for the share buyback [1]

Core Viewpoint - The company announced that its director and general manager, Han Benyi, plans to increase his stake in the company by purchasing shares in the A-share market between February 1, 2026, and July 31, 2026, with a total investment amounting to no less than 1.5 million RMB and no more than 2 million RMB, without setting a price range for the purchases [1] Group 1 - Han Benyi holds 1.98 million shares, representing 0.30% of the total share capital [1] - The planned share buyback will be conducted through centralized bidding [1] - The total investment for the share purchase is specified to be between 1.5 million RMB and 2 million RMB [1]

Group 1 - The company, Haili Biological, announced that its General Manager, Han Benyi, plans to voluntarily increase his shareholding in the company by investing between RMB 1.5 million and RMB 2 million within six months through the Shanghai Stock Exchange [1] - As of the announcement date, Han Benyi holds 1.98 million shares, which represents 0.3% of the company's total share capital [1] Group 2 - The nuclear power construction industry is experiencing a surge, with equipment manufacturers reporting high demand, leading to orders scheduled until 2028 [1] - Employees in the equipment manufacturing sector are working in three shifts, with production lines operating 24 hours a day to meet the increased demand [1]

证券代码：603718 证券简称：海利生物 公告编号：2026－006 上海海利生物技术股份有限公司 关于公司股票可能被实施退市风险警示的风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 公司控股子公司陕西瑞盛生物科技有限公司从 2025 年二季度开始，受国家政策 影响导致行业竞争者增加引发的"价格战"影响显现及原相关税收优惠政策执行收紧 落实导致其业绩出现明显下滑，原收购时所依据的股东全部权益价值已无法真实反映 其估值，因此公司与交易对手方美伦管理有限公司（以下简称"美伦公司"）签订补 充协议，根据新的评估报告调整对价，由 9.35 亿元调整为 53,570 万元，美伦公司按 补充协议约定返还交易差价 39,930 万元。公司原认为可按《企业会计准则》相关规 定直接冲减该项长期投资的初始投资成本39,930万元，并相应调减商誉39,930万元。 然而，根据进一步对《企业会计准则》等相关规定的研究，基于谨慎性原则，公司本 次业绩按将美伦公司返还的交易差价计入营业外收入，同时相应计提商誉减值准备约 39,930 ...

证券代码：603718 证券简称：海利生物 公告编号：2026-007 上海海利生物技术股份有限公司 董事兼总经理增持公司股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增持主体的基本情况 截至本公告披露日，上海海利生物技术股份有限公司（以下简称"公司"） 董事兼总经理韩本毅先生持有公司股份 1,980,000 股，占公司总股本的 0.30%。 增持计划的主要内容 基于对公司发展前景的信心和公司股票长期投资价值的认可，为维护股东利 益，增强投资者信心，公司董事兼总经理韩本毅先生计划自愿以自有或自筹资金 在本公告日起 6 个月内通过上海证券交易所交易系统以集中竞价的方式增持公 司股份，预计累计增持金额不低于人民币 150 万元，不超过人民币 200 万元。 本次增持计划不设价格区间。 增持计划无法实施风险 本次增持计划的实施可能存在因资本市场发生变化等因素，导致本次增持计 划无法达到预期的风险。如本次增持计划实施过程中出现上述风险情况，公司将 及时履行信息披露义务。 公司于 2026 年 ...

证券代码：603718 证券简称：海利生物 公告编号：2026－005 上海海利生物技术股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计公司 2025 年度实现利润总额 3,400 万元到 4,000 万元，实现归属于母公司所有者的净利润 1,100 万元到 1,600 万元，归属 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 （一）利润总额：208,117,455.78 元。归属于母公司股东的净利润： 171,180,295.61 元。归属于母公司股东的扣除非经常性损益的净利润： 10,581,377.63 元。 （二）每股收益：0.26 元。（以最新股本 651,904,700 股计算） （三）营业收入：271,039,818.26 元。 三、本期业绩下滑的主要原因 1、2024 年公司因出 ...

Core Viewpoint - The animal health sector experienced a slight decline of 0.23% on January 30, with Jinhe Biological leading the drop. The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. Group 1: Stock Performance - The closing prices and performance of key stocks in the animal health sector showed varied results, with Huisheng Biological rising by 3.51% to 29.46, while Jinhe Biological fell by 2.98% to 6.51 [1][2]. - The trading volume for Huisheng Biological was 303,100 shares, with a transaction value of 901 million yuan, indicating strong market interest [1]. Group 2: Capital Flow - The animal health sector saw a net inflow of 59.82 million yuan from institutional investors, while retail investors experienced a net outflow of 81.83 million yuan, indicating a shift in investor sentiment [2][3]. - Among individual stocks, Huisheng Biological attracted a significant net inflow of 1.23 billion yuan from institutional investors, while Jinhe Biological faced a net outflow of 543.32 million yuan [3].